

Amendments

Please amend the below claims as follows:

*D 3 5 10 15*  
An adenoviral vector as described in claim 1 or 15 wherein said deletion of said  
E1b region genes comprises p19, 55K, and pIX.

*D 3 5 10 15*  
6. An recombinant adenoviral vector as described in claim 1 or 15 wherein said  
heterologous gene encodes a protein selected from the group consisting of tumor  
necrosis factor alpha, interferon gamma, an interleukin, a cell suicide protein,  
cytosine deaminase, thymidine kinase and mif-3.

7. Cells comprising said adenoviral vectors of claim 1 or 15.

*D 3 5 10 15*  
10. A method for treating a mammal having a neoplastic condition in need of said  
treatment, comprising administering to said mammal a therapeutically effective  
dose of said adenoviral vectors of claims 1, 5, 6 or 15.

*D 3 5 10 15*  
15. A recombinant adenoviral vector comprising a deletion of E1b region gene(s), but  
retaining the E1b promoter, and substituting for said E1b region gene(s) a  
heterologous gene that is operable linked to said E1b promoter.

Remarks

In view of the above amendments reconsideration of the pending claims is  
requested.